Medicines regulator receives 46 reports of hospitalisations linked to weight-loss drugs
As of 16 August 2024, the MHRA had received 5,073 reports of common gastrointestinal reactions related to GLP-1 RA use, of which 46 reported hospitalisation of the individual.
In order to avoid falsified pens, the MHRA recommends that patients who obtain a private prescription for GLP-1 RAs “ensure this is dispensed from an authorised source, such as a registered pharmacy”
Shutterstock.com
The Medicines and Healthcare products Regulatory Agency (MHRA) has said it received 46 reports of hospitalisations associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
